The introduction of anti–vascular endothelial growth factor (VEGF) agents to treat macular edema secondary to RVO was an important advancement for the improvement of visual outcomes in patients with BRVO and CRVO [5]. The gene discussed is VEGFA; the disease is macular retinal edema.